These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32699983)

  • 1. A Review of Immune-Mediated Adverse Events in Melanoma.
    Kennedy LB; Salama AKS
    Oncol Ther; 2019 Dec; 7(2):101-120. PubMed ID: 32699983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
    Villadolid J; Amin A
    Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity management of immunotherapy for patients with metastatic melanoma.
    Linardou H; Gogas H
    Ann Transl Med; 2016 Jul; 4(14):272. PubMed ID: 27563659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
    Trinh S; Le A; Gowani S; La-Beck NM
    Asia Pac J Oncol Nurs; 2019; 6(2):154-160. PubMed ID: 30931360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological Agents Used in Cancer Treatment.
    Simsek M; Tekin SB; Bilici M
    Eurasian J Med; 2019 Feb; 51(1):90-94. PubMed ID: 30911265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
    Okuyama R
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
    Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
    Front Oncol; 2020; 10():91. PubMed ID: 32117745
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
    Kumar V; Chaudhary N; Garg M; Floudas CS; Soni P; Chandra AB
    Front Pharmacol; 2017; 8():49. PubMed ID: 28228726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.